Healthcare
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026. MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.
About this update from Mannkind Corporation
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026. MannKind's management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast of the conference call will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations . A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.
View stock analysis, news, and events for Mannkind Corporation
More from Mannkind Corporation
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Ac...
August 13, 2026
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of It...
July 29, 2026